Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Horizon

- PMLiVE

Novartis acquires DTx Pharma in deal worth up to $1bn

The agreement gives Novartis access to three preclinical neuroscience programmes

Applying Vibrotactile Stimulation to Improve Parkinson’s

Lucy Jung, CEO & Founder of Charco Neurotech, shares how meeting members of the Parkinson's community catalyzed the founding of Charco and how #innovative medical devices and software can improve...

Impetus Digital

Applying Vibrotactile Stimulation to Improve Parkinson’s

Lucy Jung, CEO & Founder of Charco Neurotech, shares how meeting members of the Parkinson's community catalyzed the founding of Charco and how #innovative medical devices and software can improve...

Impetus Digital

Cannes Lion 2022

Our Top 5 Pharma Picks From Cannes Lions

Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022.

The Good Ideas Group

Applying Vibrotactile Stimulation to Improve Parkinson’s

Lucy Jung, CEO & Founder of Charco Neurotech, shares how meeting members of the Parkinson's community catalyzed the founding of Charco and how innovative medical devices and software can improve...

Impetus Digital

Data-Driven Approaches for Neurorecovery

Yotam Drechsler (Co-founder/CEO) and Yaron Segal (Co-founder/CINO) from BrainQ Technologies dives into the roles of Brain-Computer Interface technologies and electrophysiology measurements in aiding neurorecovery, the role of AI and machine...

Impetus Digital

Biogen Idec building

Rolling submission granted for Biogen/Eisai’s next Alzheimer’s antibody

The FDA will review the data for Biogen and Eisai’s anti-amyloid beta protofibril antibody, lecanemab, on an ongoing basis

Biogen Idec building

Embattled Biogen talks up Aduhelm

Biogen CEO admitted the company was experiencing “near-term challenges” after the controversial approval of Alzheimer’s drug, Aduhelm

- PMLiVE

Congress “concerned by apparent anomalies” around FDA’s approval of Aduhelm

Congress demands more information from the FDA on its controversial approval of Biogen’s Alzheimer’s drug and its dealings with the company.

- PMLiVE

Lilly restructures in preparation for Alzheimer’s drug launch

As excitement builds around its potential Alzheimer’s drug, donanemab, Lilly has created a new neuroscience business unit, Lilly Neuroscience, to shepherd the company’s portfolio in pain and neurodegeneration

- PMLiVE

Lilly restructures in preparation for Alzheimer’s drug launch

As excitement builds around its potential Alzheimer’s drug, donanemab, Lilly has created a new neuroscience business unit, Lilly Neuroscience, to shepherd the company’s portfolio in pain and neurodegeneration

Article

A glimmer of hope for Alzheimer’s patients, but at what cost?

Research Partnership

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links